Dr. Charles Glueck MD
Director of Cholesterol Center, Jewish Hospital
Member of the Healthcare Council
Council Member Biography
Charles Glueck, MD, is the Director of Jewish Hospital Cholesterol Center in Cincinnati, Ohio. He has expertise in lipids, lipoproteins, atherosclerosis-thrombosis, thrombosis, human genetics, epidemiology, obstetrics and gynecology and hematology. Dr. Glueck has extensive published experience with ocular thrombosis, amaurosis fugax, pregnancy loss, osteonecrosis, Prinzmetal's angina and ischemic stroke. He is experienced in epidemiology and biostatistics, and design-completion of controlled clinical trials. Recently, Dr. Glueck has published six papers focusing on childhood-adolescent hyperinsulinemia and its relationship to young adult type 2 diabetes. Dr. Glueck has authored over 650 scientific papers, was an established investigator for AHA, and has been a long-term NIH grantee. He is on the editorial board of Circulation and is a senior editor of Metabolism. Dr. Glueck actively reviews for 25 journals. He has also consulted for several major drug companies. (This is me - Update Profile)
Employment History
- 1987 - Unspecified
- Director of Cholesterol Center, Jewish Hospital
GLG NewsSM Analyses by Charles Glueck
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
Study: Lab test can prevent severe blood clots in testosterone patients
September 30, 2011
A recent study finds that a blood test can prevent disastrous blood clots in men receiving testosterone therapy.
-
CETP INHIBITORS- A PROBABLE CLASS ACTION EFFECT TO BE PROATHEROGENIC
March 6, 2007
CETP INHIBITORS: A PROBABLE CLASS ACTION EFFECT TO BE PROATHEROGENIC | mediaroom.pfizer.com
By reducing fractional catabolic rate and by producing a large, cholesterol rich HDL molecule which could not easily be cleared by hepatic HDL receptors, our research group in Cincinnati thought from the beginning that the CETP inhibitors AS A CLASS would fail, and might even be proatherogenic. Regrettably, with torcetrapib this sequence of events seemed to occur. Our concern is that this is a class effect and that CETP inhibitors are not a fruitful area for further drug development.
GLG Study Groups with Charles Glueck(?)
| Study Group Name | No. Members |
|---|---|
| General Cardiologists (US) | 1362 |
| Heart Failure Specialists (US) | 1083 |
| Physicians who Treat Hypertension (US) | 949 |
| Non-Electrophysiologist Cardiologists (US) | 849 |
| Physicians who Treat Hypercholesterolemia in the U.S. | 293 |
GLG Live Meetings with Charles Glueck(?)
Recent Seminars
-
March 28, 2008 | Boston
GLGi: Lipid Management
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.